Development of drug

This section introduces the fundamentals of drug discovery and development, summarizing the roles of certain scientists who work within fipcos. It surveys preclinical discovery and chemical development, where many chemists find work. It also introduces other development efforts that occur when a clinical candidate has been chosen or when the choice nears. These efforts include drug metabolism, radiochemistry, and radioimmimology, and they also employ organic and medicinal chemists. 

---

There has been considerable focus on the development of drugs that lead to a reduction in the total amount of adipose tissue. These include agents targeted at limiting fat absorption, the inhibition of appetite, and the stimulation of energy expenditure (thermogenesis)-or a combination thereof. The best example of drugs,... 

Drug discovery is the identification and optimization of compounds for further development of drugs. 

The development of drugs that block Calcineuiin phosphatase activity has allowed successful prevention of graft rejection. Due to the key role that NFAT has in T-cell activation, these inhibitors behave as potent immunosuppressors. Nevertheless, the important roles that NFAT proteins have in other tissues suggest that exploring the use of similar drugs in other pathological contexts may be clinically and therapeutically relevant. 

The developments of drugs and devices share a common goal of producing products that are safe and effective. However, they differ in the approaches used for product... 

Taylor EM. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet 2002 41 81-92. 

In the recently released book on worldwide compliance issues (Adherence to Long-term Therapies, Evidence for Action),7 published by the World Health Organization, researchers indicate that the problem of noncompliance is worse in countries in the developing world than in countries in the industrialized world. Many parts of the United States have similar morbidity and mortality rates as countries in the Third World.8 Specific disease states may have significant additional noncompliance ramifications due to the development of drug-resistant strains of bacteria.9 Many times what is necessary is referral to specific clinicians for individualized treatment and monitoring to enhance compliance. The case histories provided in this text will allow you to follow what others have done in similar situations to optimally help patients succeed in improving compliance rates and subsequent positive health outcomes. 

While generally not of major concern, omeprazole may inhibit the metabolism of warfarin, diazepam, and phenytoin lansoprazole may decrease theophylline concentrations. Drug interactions with omeprazole are of particular concern in patients who are considered slow metabolizers, as are approximately 3% of the Caucasian population. Unfortunately, it is unclear which patients have the polymorphic gene variation that makes them slow metabolizers.17 The metabolism of esomeprazole may also be altered in patients with this polymorphic gene variation. Patients on potentially interacting drugs should be monitored for development of drug-related problems. 

Compared to those treated with placebo, 60% to 70% of patients with HBeAg-negative hepatitis B treated with lamivudine for 52 weeks have undetectable HBV DNA levels and normalization of ALT levels. However, the rate of relapse is 80% to 90% once the treatment has been discontinued.20 Lamivudine therapy beyond 12 months may be considered to sustain response, but biochemical and virologic breakthrough commonly occurs due to the development of drug resistance.29... 

Elucidation of the activities of individual COX isoforms led to the development of drugs that selectively inhibit the inducible form of the enzyme, COX-2. Thus COX-2 inhibitors were expected to minimize NSAID gastrointestinal toxicity and antiplatelet effects (see Fig. 55-3).19 A common misconception is that COX-2 inhibitors are more effective than nonselective NSAIDs in relieving pain and inflammation. In clinical trials, patients experienced similar levels of pain relief with COX-2 inhibitors and nonselective NSAIDs. 

O The treatment goals for HIV infection are to maximally and durably suppress HIV replication, avoid the development of drug resistance, restore and preserve immune function, prevent opportunistic infections, and minimize adverse effects. 

Development of drug candidate 2 was supported by providing sufficient amounts of the bulk in a short period of time. 

Table 4 Periods and Notable Events in the History of the Development of Drugs and Drug Products... 

---